CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Coenzyme Q10 +1 moredrug
Likely dose
Coenzyme Q10 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00541164
NCT00541164Phase 2Completed
CompareCT.gov

Effects of Coenzyme Q10 (CoQ10) on Subjects With Charcot-Marie-Tooth Disease (CMT):A Double Blind, Randomized, Controlled Trial With an Open Label Follow-up Study

Memorial Medical Center·interventional·Posted Oct 10, 2007·Updated Jul 15, 2013

In Brief

A Phase 2 clinical trial evaluating Coenzyme Q10 for Charcot Marie Tooth Disease. Completed, enrolled 23 participants across 1 site.

Detailed Summary

The object of this research is to test the effectiveness of Coenzyme Q10 (CoQ10) on symptoms of weakness, fatigue, and pain in persons with Charcot-Marie-Tooth disease (CMT).In this study we also intend to examine the impact of daily supplementation on overall quality of life.We are also interested in identifying any differences in serum ratios of CoQ10 in the oxidized and reduced forms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCharcot Marie Tooth Disease
CountriesUnited States
CollaboratorsUnited States Department of Defense

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 10, 2007
Enrollment StartSep 1, 2007
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 18.7 years ago

Interventions

Coenzyme Q10drug

300 mg CoQ10 twice a day for 48 weeks

Coenzyme Q10dietary

300mg CoQ10 twice a day for 24 weeks beginning at week 24 of the study